Helen Lowe’s Post

Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft

Does DDC truly disburden sites? What about the impact on monitoring and other downstream processes? How do the requirements of decentralized trials impact EDC and DDC systems? Join Clinical ink's Megan Petrylak, PMP as we explore the use of advantages and disadvantages of EDC and DDC and the benefits of a hybrid collection model where the site can choose.

What is Launch to Excellence? It’s the perfect opportunity for you to connect with MDRT members from around the world. This engaging kickoff session is designed to help maximize your MDRT membership and meeting experience. Hear from seasoned MDRT members who will share insights and advice as they pass along their secrets of success. https://bit.ly/3wdhJwT

UP RERA Update ! As per update from UP RERA on 19th May 2024 All promoters are required to update the details of their Authorized Representatives for both administrative and legal purposes on the UP RERA portal through their login dashboard. The Authorized Representatives appointed by the promoter for administrative purposes will handle all correspondence with RERA regarding project matters, including registration, extensions, editing, QPR, late fees, and penalties. Similarly, the Representatives nominated for legal purposes will handle complaint-related matters, including signing documents such as replies to complaints filed before the honorable benches and signing settlement agreements with complainants on behalf of the company. Presently, only 250 promoters have provided information for their Legal Representatives. Therefore, Information received from rest of promoters regarding administrative side shall be used for complaint side also. Defaulters may face difficulties in correspondence with RERA. Please ensure that the details of your Authorized Representatives are accurate and up to date on the RERA portal to avoid any potential issues or delays in the administration or legal proceedings related to your project.

Hope to connect with you as we discuss the balance of interconnectedness and autonomy! 

Are you attending the 2024 Safety Pharmacology Society Annual Meeting? Are you ready to share your science at the DSI Data Blast?💥 THE BLAST IS BACK and there’s 1️⃣ week left to submit your abstract and ✅ the box for Blast participation. SPS abstract submission ➡️ https://ow.ly/RA5m50R3LVy #2024SPS #safetypharmacology #drugdiscovery

Xrayser: Unity is vital. Is now the time for the IPA to go up against the NPA? https://ow.ly/4nUN50RzFgR? This month, Xrayser talks about how the importance of unity in dealing with the government, and ahead of the much-deserved upcoming awards season.

Consultants, does your PHIN profile have a photo? It takes less than 5 minutes to add a photo to your profile and become more visible to the 36,000 – 40,000 patients who visit our website each month. Most consultants already have a professional photo on other sites, which can also be used on your PHIN profile. Read our guide on how to edit and update your profile: https://lnkd.in/e3yZKh2J If you have any questions about PHIN or need support with PHIN-related activities, such as activating your account, submitting your fees or you would like to know more about the patient feedback information that we publish, or how to get your profile noticed on our website – book a virtual session today. If you are aware of any consultants and/or their secretaries who may benefit from attending a session, ask them to contact us at: [email protected] or call 0203 823 7518.

If you’re looking for me tomorrow, you can find me here👇🏻👇🏻👇🏻👇🏻Looking forward to an insightful discussion on integrating QbD & RBM approaches in the conduct of clinical trials!